La prognosi dal tumôr dal polmon e dipent di diviers fatôrs, includût il stadi dal tumôr, il tip di tumôr dal polmon e la salût gjenerâl dal pazient.
Il cancar ai polmons no a celulis piçulis, che al è il tip plui comun, al à un tas di sorevivence a 5 agns di cirche il 18% par dutis lis fasis cumbinadis. ❚
Dut câs, se il cancar al è cjatât in timp, il tas di sorevivence a 5 agns al pues jessi alt fin al 57%.
Al è impuartant notâ che chestis a son statistichis gjenerâls e i risultâts individuâi a puedin variâ.
Lis opzions di cure e i progrès de medisine a van indenant a miorâ, e tancj pazients a puedin vivi plui a lunc e vê une cualitât di vite miôr cun curis e gjestion adeguadis.
Martini B: [Lung cancer--epidemiology, prognosis and therapy]. Med Monatsschr Pharm. 2006, 29 (6): 217-21.
Zou T, Liu JY, She L, Yin JY, Li X, Li XP, Zhou HH, Chen J, Liu ZQ: The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Pharmacol. 2020, 11 (): 1029.
Li L, Zhou Q, Luo D, Xu Y, Yang H, Zhang S, Li A, Li H, Lv C: [A study on the relationship between lung cancer cell apoptosis and prognosis in patients with human non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 1998, 1 (2): 70-3.
Feng YY, Yang Y, Wang YY, Bai XX, Hai P, Zhao R: [Hypomethylation of DAPL1 associated with prognosis of lung cancer patients with EGFR Del19 mutation]. Zhonghua Zhong Liu Za Zhi. 2021, 43 (12): 1264-1268.
Xiao Y, Zhu S, Yin W, Liu X, Hu Y: IGFBP-4 expression is adversely associated with lung cancer prognosis. Oncol Lett. 2017, 14 (6): 6876-6880.
Lang J, Zhao Q, He Y, Yu X: Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers. 2018, 23 (6): 518-526.
['Disclaimer: medicâl']
['Chest sît web al è furnît dome par fins educatîfs e informatîfs e nol è une consulence o un servizi professionâl.']
['Lis informazions furnidis no àn di jessi dopradis par diagnosticâ o curâ un probleme di salût o une malatie, e chei che a vuelin une consulence mediche personâl a àn di consultâ un miedi autorizât.']
['Par plasê note che la rêt neuronâl che a gjenere lis rispuestis aes domandis, e je imprecise soredut cuant a si trate di contignûts numerics.']
['Cîr simpri la consulence dal to miedi o di un altri professionist in materie di salût a rivuart di une malatie. No sta mai dismenteâ la consulence di un miedi professionist o intardâti a cirîle par vie di alc che tu âs let su chest sît. Se tu pensis di vê une emergjence mediche, clame il 911 o va tal pronto socorso plui dongje.']
['Disclaimer: copyright']
['Il Digital Millennium Copyright Act dal 1998, 17 U.S.C. § 512 (il DMCA) al proviôt un ricors pai proprietaris di copyright che a crodin che il materiâl che al comparìs su Internet al violi i lôr dirits sot la leç sul copyright dai Stâts Unîts. ']
['Se tu crodis in buine fede che cualsisei contignût o materiâl disponibil in conession cul nestri sît o i nestris servizis al violi il tô copyright, tu (o il to agjent) tu puedis mandânus une notifiche domandant la rimozion dal contignût o dal materiâl, o il bloc dal acès. ']
['I avîs a àn di jessi mandâts par scrit vie e-mail (cjale la sezion "Contat" par vê l\'indiriç e-mail). ']
['La DMCA e domande che la tô notifiche di violazion dal copyright e vedi dentri chestis informazions: (1) descrizion dal lavôr protet dal copyright che al è ogjet de violazion rivendicade; (2) descrizion dal presunt contignût che al è une violazion e informazions suficientis par permeti di cjatâ il contignût; (3) informazions di contat, includût la tô direzion, numar di telefon e pueste eletroniche; (4) une declarazion di buine fede che il contignût al no è autorizât dal proprietari dal copyright, o dal so agjent, o par vie di une leç; ']
['5) une declarazion di bande tô, firmade sot pena di falsetât, che lis informazions inte notifiche a son veris e che tu âs la autoritât par fâ valê i dirits di autôr che a son stâts violats;']
['e (6) une firme fisiche o eletroniche dal titulâr dal copyright o di une persone autorizade a agjî par cont dal titulâr. ']
['Se no tu âs dutis lis informazions parsore, al podarès intardâ il tratament dal to reclam.']
['Contatât']
['Par plasê mandinus une e-mail cun ogni domande / sugjeriment.']
What is prognosis of lung cancer?
The prognosis of lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the overall health of the patient.
Non-small cell lung cancer, which is the most common type, has a 5-year survival rate of about 18% for all stages combined.
However, if the cancer is caught early, the 5-year survival rate can be as high as 57%. Small cell lung cancer, which is less common, has a 5-year survival rate of about 7% for all stages combined.
It is important to note that these are general statistics and individual outcomes may vary.
Treatment options and advancements in medicine continue to improve, and many patients can live longer and have a better quality of life with proper care and management.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['A rivuart']
['BioMedLib al dopre ordenadôrs automatics (algoritmi di aprendiment de machine) par gjenerâ cubiis di domandis e rispuestis.']
['Si scomence cun 35 milions di publicazions biomedichis di PubMed/Medline. e ancje lis pagjinis web di RefinedWeb.']
